Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
20–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
CD20 and CD22-positive, B-cell NHL which has progressed after 1 or 2 prior therapies.
Prior therapy must have contained at least one dose of Rituximab therapy. Patients can not be refractory to Rituximab (refractory = PD under treatment or within 6 month
Eastern Cooperative Oncology Group (ECOG) performance status: 0/ 1.
Patients must not have received previous radioimmunotherapy.
Patients tolerant to Rituximab.
Patients must not have received chemotherapy, cancer immunosuppressive therapy, growth factors (except erythropoietin), or investigational agents within 28 days before first dose of test article.
You may not be if
Candidate for potentially curative therapies
Subjects must not have received previous radioimmunotherapy.
Subjects with autologous hematopoietic stem cell transplant within the last 6 months
Clareo Health | Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab
